Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics.

Hdl Handle:
http://hdl.handle.net/10147/209094
Title:
Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics.
Authors:
Shanahan, F
Affiliation:
Department of Medicine, Cork University Hospital and National University of, Ireland, Cork, Ireland. Fshanahan@ucc.ie
Citation:
Gastroenterology. 2001 Feb;120(3):622-35.
Journal:
Gastroenterology
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/209094
PubMed ID:
11179240
Abstract:
Treatment options for inflammatory bowel disease (IBD) reflect a continuing shift from empiricism to strategies based on improved understanding of the pathophysiology of disease. In susceptible individuals, IBD appears to be the result of defective regulation of mucosal immune interactions with the enteric microflora. This has prompted research directed at the interface of the traditional disciplines of immunology, microbiology, and epithelial cell biology. Whereas immunodiagnostics have been of limited clinical value in IBD, assessments of mucosal rather than systemic immune function are promising. Therapeutically, there is an increasing trend toward more aggressive and earlier use of immunomodulatory agents, particularly for prevention of relapse, with cytokine manipulation as a bridge therapy to achieve remission in patients with acute severe disease. Although most drug treatments are directed toward altering the host response, the rationale for manipulating the enteric flora appears sound and will be the basis of additional future therapeutic strategies. Notwithstanding the widening range of options for drug therapy in IBD, other outcome modifiers and well-established principles of managing chronic disease are as important as ever.
Language:
eng
MeSH:
Gene Therapy; Humans; Immunosuppressive Agents/therapeutic use; Inflammatory Bowel Diseases/diagnosis/immunology/*therapy; Matrix Metalloproteinases/antagonists & inhibitors; Probiotics/therapeutic use; Tumor Necrosis Factor-alpha/antagonists & inhibitors
ISSN:
0016-5085 (Print); 0016-5085 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorShanahan, Fen_GB
dc.date.accessioned2012-02-03T15:12:07Z-
dc.date.available2012-02-03T15:12:07Z-
dc.date.issued2012-02-03T15:12:07Z-
dc.identifier.citationGastroenterology. 2001 Feb;120(3):622-35.en_GB
dc.identifier.issn0016-5085 (Print)en_GB
dc.identifier.issn0016-5085 (Linking)en_GB
dc.identifier.pmid11179240en_GB
dc.identifier.urihttp://hdl.handle.net/10147/209094-
dc.description.abstractTreatment options for inflammatory bowel disease (IBD) reflect a continuing shift from empiricism to strategies based on improved understanding of the pathophysiology of disease. In susceptible individuals, IBD appears to be the result of defective regulation of mucosal immune interactions with the enteric microflora. This has prompted research directed at the interface of the traditional disciplines of immunology, microbiology, and epithelial cell biology. Whereas immunodiagnostics have been of limited clinical value in IBD, assessments of mucosal rather than systemic immune function are promising. Therapeutically, there is an increasing trend toward more aggressive and earlier use of immunomodulatory agents, particularly for prevention of relapse, with cytokine manipulation as a bridge therapy to achieve remission in patients with acute severe disease. Although most drug treatments are directed toward altering the host response, the rationale for manipulating the enteric flora appears sound and will be the basis of additional future therapeutic strategies. Notwithstanding the widening range of options for drug therapy in IBD, other outcome modifiers and well-established principles of managing chronic disease are as important as ever.en_GB
dc.language.isoengen_GB
dc.subject.meshGene Therapyen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunosuppressive Agents/therapeutic useen_GB
dc.subject.meshInflammatory Bowel Diseases/diagnosis/immunology/*therapyen_GB
dc.subject.meshMatrix Metalloproteinases/antagonists & inhibitorsen_GB
dc.subject.meshProbiotics/therapeutic useen_GB
dc.subject.meshTumor Necrosis Factor-alpha/antagonists & inhibitorsen_GB
dc.titleInflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics.en_GB
dc.contributor.departmentDepartment of Medicine, Cork University Hospital and National University of, Ireland, Cork, Ireland. Fshanahan@ucc.ieen_GB
dc.identifier.journalGastroenterologyen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.